Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY3018250 · 1 trial · 2 indications
Area under the curve (AUC) with respect to the measurement time points at 6 hours, 24 hours, 7 days and 30 days of the ratio to baseline of clot burden
The classify of bleeding events use the International Society on Thrombosis and Haemostasis (ISTH) definitions.
| Arm | Type | Description |
|---|---|---|
| BAY3018250 Dose 1 | EXPERIMENTAL | Participants will receive BAY3018250 Dose 1. |
| BAY3018250 Dose 2 | EXPERIMENTAL | Participants will receive BAY3018250 Dose 2. |
| Placebo to BAY3018250 | PLACEBO_COMPARATOR | Participants will receive placebo to BAY3018250. |
| Name | Type | Description |
|---|---|---|
| BAY3018250 | DRUG | Dose 1 or dose 2 of BAY3018250 |
| Placebo to BAY3018250 | DRUG | Matching placebo to BAY3018250 |
Inclusion Criteria: * Male and female (if postmenopausal or hysterectomized) aged 18 years or older * Acute symptomatic proximal deep vein thrombosis (DVT) documented by compression ultrasound (CUS) and all of the following: * duration of symptoms 14 days or less * Proximal DVT involving at le...
BAY3018250 is an investigational small molecule being developed for thrombolysis and for acute venous and arterial thrombotic and thromboembolic events. It has been studied in patients with symptomatic proximal deep vein thrombosis and in healthy volunteers. The drug is currently in Phase 2 clinical development.
BAY3018250 is a small molecule designed for thrombolysis, meaning it is intended to break down blood clots. Its specific molecular target has not been disclosed in the available information. The drug is being evaluated for its ability to treat acute venous and arterial thrombotic and thromboembolic events.
BAY3018250 is being developed by Bayer AG, a German pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker BAYRY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for thrombolysis and thrombotic conditions.
BAY3018250 is in Phase 2 clinical development. It has completed a Phase 2 trial in patients with proximal deep vein thrombosis and two Phase 1 trials in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
BAY3018250 has completed three clinical trials. NCT06149520 was a Phase 2 study in 283 patients with symptomatic proximal deep vein thrombosis. NCT06562985 was a Phase 1 study in 39 healthy Japanese men, and NCT06619483 was a Phase 1 study in 24 healthy Chinese participants.
No alternative names for BAY3018250 have been disclosed. The drug is identified solely by its code name BAY3018250 in clinical trial registries and available information. It is an investigational small molecule being developed by Bayer AG.